299. Cystic fibrosis
1,592 clinical trials,   1,539 drugs   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
22 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04378153
(ClinicalTrials.gov)
August 25, 20204/5/2020Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator TherapyA Master Protocol to Test the Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY)Cystic FibrosisOther: Discontinuation of hypertonic saline (HS);Other: Continuation of hypertonic saline (HS);Other: Discontinuation of dornase alfa (dnase);Other: Continuation of dornase alfa (dnase)David Nichols, MDCystic Fibrosis Foundation;Dartmouth-Hitchcock Medical Center;University of WashingtonRecruiting12 YearsN/AAll800N/AUnited States
2NCT04437641
(ClinicalTrials.gov)
October 22, 201926/3/2020Impact of Pediatrician Intervention on the Smoking Habits of Parents of Sick ChildrenImpact of Pediatrician Intervention on the Smoking Habits of Parents of Children With Cystic Fibrosis, Type 1 Diabetes or Children Hospitalized for a First Episode of Bronchiolitis.Tobacco Consumption;BronchiolitisOther: Tobacco questionnaireUniversity Hospital, ToulouseNULLRecruiting18 Years65 YearsAll600France
3NCT04056702
(ClinicalTrials.gov)
September 5, 201927/7/2019Impact of Triple Combination CFTR Therapy on Sinus Disease.Impact of Elexacaftor-tezacaftor-ivacaftor Triple Combination CFTR Therapy on Sinus Disease: Quantitative Sinus Computed Tomography, Patient Reported Outcomes and Cellular and Molecular ChangesCystic FibrosisDrug: Elexacaftor-tezacaftor-ivacaftor exposureJennifer Taylor-CousarCystic Fibrosis FoundationActive, not recruiting18 Years89 YearsAll30United States
4NCT03795363
(ClinicalTrials.gov)
April 10, 201928/12/2018Orkambi Treatment in 2 to 5 Year Old Children With CFNutritional Impact of Orkambi Treatment in 2 to 5 Year Old Children Homozygous for F508del MutationsCystic FibrosisDrug: OrkambiChildren's Hospital of PhiladelphiaVertex Pharmaceuticals IncorporatedRecruiting2 Years5 YearsAll32United States
5NCT03783286
(ClinicalTrials.gov)
February 6, 201918/12/2018Ivacaftor Treatment in 6 Month to 2 Year Old CF SubjectsNutritional Impact of Ivacaftor Treatment in 6 Month to 2 Year Old Children With CF Gating MutationsCystic FibrosisDrug: IvacaftorChildren's Hospital of PhiladelphiaVertex Pharmaceuticals IncorporatedRecruiting6 Months2 YearsAll18United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03625466
(ClinicalTrials.gov)
August 10, 20187/8/2018A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508delAn Exploratory Phase 2, 2-part, Randomized, Double-blind, Placebo-controlled Study With a Long-term, Open-label Period to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508delCystic FibrosisDrug: LUM;Drug: IVA;Drug: Matched PlacebosVertex Pharmaceuticals IncorporatedNULLActive, not recruiting2 Years5 YearsAll51Phase 2Germany
7EUCTR2017-003761-99-DE
(EUCTR)
27/06/201819/02/2018A Study of the Effects of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508delAn Exploratory Phase 2, 2-part, Randomized, Double blind, Placebo controlled Study With a Long term, Open label Period to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del Cystic Fibrosis
MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: lumacaftor / ivacaftor
Product Code: VX-809 / VX-770
INN or Proposed INN: LUMACAFTOR
Other descriptive name: LUMACAFTOR
INN or Proposed INN: IVACAFTOR
Product Name: lumacaftor / ivacaftor
Product Code: VX-809 / VX-770
INN or Proposed INN: LUMACAFTOR
Other descriptive name: LUMACAFTOR
INN or Proposed INN: IVACAFTOR
Trade Name: Orkambi 100 mg/125 mg film-coated tablets
Product Name: LUM/IVA fixed-dose combination
INN or Proposed INN: LUMACAFTOR
Other descriptive name: LUMACAFTOR
INN or Proposed INN: IVACAFTOR
Other descriptive name: IVACAFTOR
Vertex Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 2Germany
8NCT03492567
(ClinicalTrials.gov)
April 25, 20183/4/2018Study of Circulating Blood Cell Monocytes as Predictive Biomarker of Bone Cystic Fibrosis Disease. Impact of CFTR Correctors.Study of Circulating Monocytes as Predictive Biomarker of Osteoclastogenesis in Cystic Fibrosis-related Bone Loss. Impact of CFTR Correctors.Cystic FibrosisBiological: Blood testAssistance Publique - Hôpitaux de ParisVaincre la MucoviscidoseCompleted18 YearsN/AAll25N/AFrance
9NCT02750501
(ClinicalTrials.gov)
July 20, 201620/4/2016Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) StudyAbsorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study in Patients With Cystic Fibrosis Receiving Enteral FeedingCystic FibrosisDevice: RELiZORB (immobilized lipase) cartridge;Other: Impact Peptide 1.5Alcresta Therapeutics, Inc.Cystic Fibrosis FoundationCompleted4 YearsN/AAll49N/AUnited States
10NCT02734810
(ClinicalTrials.gov)
June 20166/4/2016SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic FibrosisA Phase 3, Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic InsufficiencyExocrine Pancreatic Insufficiency;Cystic FibrosisDrug: Liprotamase Powder for Oral SolutionAnthera PharmaceuticalsNULLCompletedN/AN/AAll15Phase 3United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT02496780
(ClinicalTrials.gov)
August 201518/6/2015The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis PatientsThe Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis PatientsCystic FibrosisDrug: novolog insulin;Drug: levemir insulin;Drug: placeboUniversity of MinnesotaNULLRecruiting10 Years25 YearsAll80Phase 2;Phase 3United States
12NCT02569229
(ClinicalTrials.gov)
June 201512/8/2015Glucose Tolerance in Children With Cystic FibrosisGlucose Tolerance and Its Clinical Impact in Children and Adolescents With Cystic FibrosisGlucose Intolerance;Cystic FibrosisOther: Diagnostics for glucose tolerance with 3 different methods.Christoph SanerUniversity Hospital Inselspital, BerneActive, not recruiting10 Years20 YearsAll14Switzerland
13EUCTR2011-000801-39-ES
(EUCTR)
25/07/201425/04/2014Placebo controlled clinical study to evaluate efficacy and safety of an antibody derived from hens? eggs building a barrier in the respiratory tract against the Pseudomonas germ in order to prevent infection with Pseudomonas in patients suffering from cystic fibrosisProspective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients - IMPACTT-PsAer-IgY Cystic fibrosis (CF) is a chronic and progressive genetic disease of the body's exocrine glands. CF especially affects the respiratory system. A common effect leads to massive production of abnormal mucus of high viscosity, which clogs the airways and leads to infections. Pulmonary infections are major causes of morbidity and mortality. Pseudomonas aeruginosa (PA) infections are most common in CF patients and chronic infection with PA ultimately occurs in virtually all patients.
MedDRA version: 16.1;Level: LLT;Classification code 10011764;Term: Cystic fibrosis NOS;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Product Name: avian polyclonal IgY antibody against PA
Product Code: PsAer IgY
INN or Proposed INN: IgY
Mukoviszidose Institute gGmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 3Hungary;Spain;Ireland;Austria;Germany;Italy;Sweden
14EUCTR2011-000801-39-AT
(EUCTR)
11/06/201424/04/2014Placebo controlled clinical study to evaluate efficacy and safety of an antibody derived from hens’ eggs building a barrier in the respiratory tract against the Pseudomonas germ in order to prevent infection with Pseudomonas in patients suffering from cystic fibrosisProspective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients - IMPACTT-PsAer-IgY Cystic fibrosis (CF) is a chronic and progressive genetic disease of the body's exocrine glands. CF especially affects the respiratory system. A common effect leads to massive production of abnormal mucus of high viscosity, which clogs the airways and leads to infections. Pulmonary infections are major causes of morbidity and mortality. Pseudomonas aeruginosa (PA) infections are most common in CF patients and chronic infection with PA ultimately occurs in virtually all patients.
MedDRA version: 16.1;Level: LLT;Classification code 10011764;Term: Cystic fibrosis NOS;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Product Name: avian polyclonal IgY antibody against PA
Product Code: PsAer IgY
INN or Proposed INN: IgY
Mukoviszidose Institute gGmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 3Hungary;Ireland;Austria;Germany;Italy;Sweden
15EUCTR2011-000801-39-HU
(EUCTR)
22/05/201403/04/2014Placebo controlled clinical study to evaluate efficacy and safety of an antibody derived from hens’ eggs building a barrier in the respiratory tract against the Pseudomonas germ in order to prevent infection with Pseudomonas in patients suffering from cystic fibrosisProspective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients - IMPACTT-PsAer-IgY Cystic fibrosis (CF) is a chronic and progressive genetic disease of the body's exocrine glands. CF especially affects the respiratory system. A common effect leads to massive production of abnormal mucus of high viscosity, which clogs the airways and leads to infections. Pulmonary infections are major causes of morbidity and mortality. Pseudomonas aeruginosa (PA) infections are most common in CF patients and chronic infection with PA ultimately occurs in virtually all patients.
MedDRA version: 16.1;Level: LLT;Classification code 10011764;Term: Cystic fibrosis NOS;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Product Name: avian polyclonal IgY antibody against PA
Product Code: PsAer IgY
INN or Proposed INN: IgY
Mukoviszidose Institute gGmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 3Hungary;Ireland;Germany;Italy;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT02048592
(ClinicalTrials.gov)
September 201316/12/2013Impact of Immunonutrition on the Patients With Cystic FibrosisImpact of Immunonutrition on the Patients With Cystic FibrosisCystic Fibrosis;Malnutrition;Oxidative StressDietary Supplement: Impact-Nutridrink;Dietary Supplement: Nutridrink-ImpactUniversity Hospital, MotolNULLRecruiting18 Years40 YearsBoth30Phase 4Czech Republic
17EUCTR2011-000801-39-IE
(EUCTR)
07/05/201312/02/2013Placebo controlled clinical study to evaluate efficacy and safety of an antibody derived from hens’ eggs building a barrier in the respiratory tract against the Pseudomonas germ in order to prevent infection with Pseudomonas in patients suffering from cystic fibrosisProspective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients - IMPACTT-PsAer-IgY Cystic fibrosis (CF) is a chronic and progressive genetic disease of the body's exocrine glands. CF especially affects the respiratory system. A common effect leads to massive production of abnormal mucus of high viscosity, which clogs the airways and leads to infections. Pulmonary infections are major causes of morbidity and mortality. Pseudomonas aeruginosa (PA) infections are most common in CF patients and chronic infection with PA ultimately occurs in virtually all patients.
MedDRA version: 16.1;Level: LLT;Classification code 10011764;Term: Cystic fibrosis NOS;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Product Name: avian polyclonal IgY antibody against PA
Product Code: PsAer IgY
INN or Proposed INN: IgY
Mukoviszidose Institute gGmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 3Ireland;Germany;Italy;Sweden
18EUCTR2011-000801-39-IT
(EUCTR)
20/06/201221/06/2012Placebo controlled clinical study to evaluate efficacy and safety of an antibody derived from hens'eggs building a barrier in the respiratory tract against Pesudomonas germ in order to preventi infection with Pseudomonas in patients suffering from cystic fibrosisProspective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients - IMPACTT -PsAer-IgY Cystic fibrosis (CF) is a chronic and progressive genetic disease of the body's exocrine glands. CF especially effects the respiratory system. A common effect leads to massive production of abnormal mucus of high viscosity, which clogs the airways and leads to infections. Pulmonary infections are major causes of morbility and mortality. PA infections are most common in CF patients and chronic infection with PA ultimately occurs in virtually all patients.
MedDRA version: 14.1;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Product Name: avian polyclonal IgY antibody against PA
Product Code: PsAer IgY
INN or Proposed INN: IgY
MUKOVISZIDOSE E.V.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
180Phase 3Germany;Italy;Sweden
19EUCTR2011-000801-39-BE
(EUCTR)
26/04/201209/01/2012Placebo controlled clinical study to evaluate efficacy and safety of an antibody derived from hens’ eggs building a barrier in the respiratory tract against the Pseudomonas germ in order to prevent infection with Pseudomonas in patients suffering from cystic fibrosisProspective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients - IMPACTT-PsAer-IgY Cystic fibrosis (CF) is a chronic and progressive genetic disease of the body's exocrine glands. CF especially affects the respiratory system. A common effect leads to massive production of abnormal mucus of high viscosity, which clogs the airways and leads to infections. Pulmonary infections are major causes of morbidity and mortality. Pseudomonas aeruginosa (PA) infections are most common in CF patients and chronic infection with PA ultimately occurs in virtually all patients.
MedDRA version: 16.1;Level: LLT;Classification code 10011764;Term: Cystic fibrosis NOS;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Product Name: avian polyclonal IgY antibody against PA
Product Code: PsAer IgY
INN or Proposed INN: IgY
Mukoviszidose Institute gGmbHNULLNot RecruitingFemale: yes
Male: yes
180Phase 3Hungary;Spain;Belgium;Ireland;Austria;Germany;Italy;Sweden
20EUCTR2011-000801-39-SE
(EUCTR)
08/02/201213/12/2011Placebo controlled clinical study to evaluate efficacy and safety of an antibody derived from hens’ eggs building a barrier in the respiratory tract against the Pseudomonas germ in order to prevent infection with Pseudomonas in patients suffering from cystic fibrosisProspective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients - IMPACTT-PsAer-IgY Cystic fibrosis (CF) is a chronic and progressive genetic disease of the body's exocrine glands. CF especially affects the respiratory system. A common effect leads to massive production of abnormal mucus of high viscosity, which clogs the airways and leads to infections. Pulmonary infections are major causes of morbidity and mortality. Pseudomonas aeruginosa (PA) infections are most common in CF patients and chronic infection with PA ultimately occurs in virtually all patients.
MedDRA version: 14.1;Level: LLT;Classification code 10011764;Term: Cystic fibrosis NOS;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Product Name: avian polyclonal IgY antibody against PA
Product Code: PsAer IgY
INN or Proposed INN: IgY
Mukoviszidose Institute gGmbHNULLNot RecruitingFemale: yes
Male: yes
180Phase 3Hungary;Spain;Belgium;Ireland;Austria;Germany;Italy;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21EUCTR2011-000801-39-DE
(EUCTR)
31/08/201104/04/2011Placebo controlled clinical study to evaluate efficacy and safety of an antibody derived from hens’ eggs building a barrier in the respiratory tract against the Pseudomonas germ in order to prevent infection with Pseudomonas in patients suffering from cystic fibrosisProspective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients - IMPACTT-PsAer-IgY Cystic fibrosis (CF) is a chronic and progressive genetic disease of the body's exocrine glands. CF especially affects the respiratory system. A common effect leads to massive production of abnormal mucus of high viscosity, which clogs the airways and leads to infections. Pulmonary infections are major causes of morbidity and mortality. Pseudomonas aeruginosa (PA) infections are most common in CF patients and chronic infection with PA ultimately occurs in virtually all patients.
MedDRA version: 17.1;Level: LLT;Classification code 10011764;Term: Cystic fibrosis NOS;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
Product Name: avian polyclonal IgY antibody against PA
Product Code: PsAer IgY
INN or Proposed INN: IgY
Mukoviszidose Institute gGmbHNULLNot RecruitingFemale: yes
Male: yes
180Phase 3Hungary;Spain;Belgium;Ireland;Austria;Germany;Italy;Sweden
22NCT01031706
(ClinicalTrials.gov)
September 200911/12/2009Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic FibrosisSustained Impact of Hypertonic Saline on Mucociliary Clearance in Young Children With Cystic FibrosisCystic FibrosisDrug: Hypertonic Saline;Drug: PlaceboUniversity of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)Completed5 Years12 YearsAll23N/AUnited States